professional assistance, which can promote higher compliance and aid in widespread use of the method in clinical medicine and health examinations. Urinary DNA can be obtained from two components, which are easily separated by centrifugation: ucfDNA from the urine supernatant and cellular DNA from the urine cell sediment. 2 Moreover, ucfDNA has more tumor-derived DNA and allows for better detection of key genomic biomarkers than cellular DNA. Thus, it serves as a promising resource for robust tumor profiling with the potential to influence clinical decisions via noninvasive patient interventions. 3 Recently, there have been more studies focused on ucfDNA.
UcfDNA quantity and a high integrity of the fragments are critical for potential diagnostic and prognostic biomarker detection of bladder cancer. [4] [5] [6] [7] [8] Studies about the distribution of ucfDNA fragments indicated that the higher molecular weight DNA, greater than 1 kb, is an important feature of ucfDNA. [9] [10] [11] UcfDNA is also a promising biomarker for tumor liquid biopsy and has been used to detect tumor-derived genes based on its high tumor genome load;
this can also allow detection of tumor-derived gene mutations.
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Even tumor-derived genes from liver cancer, 15 lung cancer, 16 colorectal cancer, [17] [18] [19] and breast cancer 20 have been detected in ucfDNA.
However, nuclease activity, especially DNase I activity, in urine is higher than in blood, as much as 100-fold more, and DNase II activity is also higher. 9 These conditions make ucfDNAs prone to degradation. To mitigate this problem, some researchers have added EDTA or EDTA-K 3 solution to urine samples to inhibit nuclease activity. 5, [21] [22] [23] [24] [25] [26] [27] [28] Other precautions such as using a sterile container to collect urine 4, 8, [29] [30] [31] and keeping urine samples at 4°C 6, 32 or on ice 3 to reduce nuclease activity. Unfortunately, these procedures make urine collection and transport inconvenient and may threaten the stability of the ucfDNA. Therefore, it is necessary to develop new methods that can allow for easy urine sample collection and preservation of the original proportion and integrity of ucfDNA, while maintaining urine cells in their original, damagefree states. In our study, we developed such a method to keep the original proportion and integrity of ucfDNA from patients with bladder cancer.
| ME THODS AND MATERIAL S

| Donor recruitment
Patients with bladder cancer were recruited from XiangYa Hospital of Central South University, Changsha, China. This study was approved by XiangYa Hospital Medical Ethics Committee acting as the Institutional Review Board in Central South University, and an informed consent form was provided and collected from all donors before urine collection. A total of 24 patients with bladder cancer were recruited: Fifteen donors were recruited for normal room temperature tests, and another 9 donors were recruited for shipping tests.
| Urine collection
At least 160 mL of first-morning urine was collected into a special urine cup from each donor and then quickly divided into two groups of tubes with 10 mL of urine each: for this trial, 
| Sample processing and grouping
The In brief, the original proportion and integrity of ucfDNA tends to be affected in two aspects: the degradation of ucfDNA and the release of cellular DNA from urine cell sediments. Therefore, we investigated the preservative effect of UCTs on these two aspects by centrifuging at 1600× g for 10 minutes to separate urine supernatant and urine cell sediment.
| UcfDNA isolation
Before isolation, urine samples were centrifuged at 1600× g for 10 minutes; then, 1.9 mL of urine supernatant was carefully transferred to new 2-mL tubes and centrifuged again at 16 000× g, 4°C for 10 minutes. Then, 1.8 mL of urine supernatant was purified by commercial MagMAX™ Cell-Free DNA Isolation kit (Applied Biosystems Inc., Foster City, CA, USA). According to the manufacturer's protocol, ucfDNA was isolated through treating the samples with proteinase K (Tiangen, Beijing, China), and ucfDNA was eluted in 50 μL of elution solution and stored at −80°C until for further analysis. Then, a sample from same time point for each group was extracted in triplicate.
| UcfDNA quantification
The concentration of ucfDNA samples was measured by Qubit™ 
| UcfDNA fragment tests
The 2-hours ucfDNA samples that had concentrations greater than 4.0 ng/μL, according to the results of ucfDNA quantification by Qubit ™ 3.0 Fluorometer, were tested by the Agilent 2200
TapeStation system (Agilent Technologies, USA) to obtain a relatively high-quality electropherogram. Operations were conducted according to manufacturer's protocol, and 2 μL of each ucfDNA sample was used in this test.
| Library preparation and massively parallel DNA sequencing
DNA libraries were prepared with up to 30 ng ucfDNA by using KAPA LTP Library Preparation Kit (KAPA Biosystems, USA) following the manufacturer's instructions. Molecular barcodes were used to minimize the background noise. Multiplex PCR was conducted using the QIAGEN Multiplex PCR Plus Kit (Qiagen, Germany) according to the product handbook. DNA sequencing was performed by an Illumina X Ten sequencer using the 150-bp paired-end mode.
UcfDNA from groups B and D for 2 hours and 7 days was conducted for this experiment. Control experiments were carried out in group B.
Five samples-No. 2, 5, 6, 7, and 9-were chosen to finish this test.
| Sequencing data analysis
An in-house data analysis pipeline was used and is summarized as 
| Statistical analysis
Python package scipy was used to calculate P-value and confidence interval. We performed stats.ttest_ind () for a two-tailed t test for pairwise comparisons, and stats.t.interval () was used to estimate confidence intervals for each group.
| RE SULTS
| UcfDNA degradation was relatively extensive under normal conditions
To study ucfDNA degradation, 15 urine samples were collected and stored at room temperature. UcfDNA degradation is visualized in 
| Stabilization of ucfDNA from preserved urine
Given that ucfDNA degradation is serious, the methods to preserve ucfDNA are necessary for the study of urine. Thus, we F I G U R E 2 Preservative effect of ucfDNA through UCTs. Urine samples were collected from 15 patients and placed at ambient temperature. Groups A and B were, respectively, expressed samples without urinary cells and with urinary cells by using normal tubes, and groups C and D were, respectively, expressed samples without urinary cells and with urinary cells by using UCTs. In each box plot, the line inside of the box indicates the median value; the limits of the box indicate the 75th and 25th percentiles. The upper and lower error bars, respectively, represent the 5th and 95th percentiles. The uppermost and lowermost plots represent the maximum and minimum values. Over time, statistically significant ucfDNA changes were not observed in groups C and D. Statistically significant ucfDNA time-dependent degradation was only observed in groups A and B (*P < 0.05, **P < 0.01, ***P ≤ 0.001 by paired Student's t test) at 2 hours, there was no significant change at 24 hours, but an obvious peak among 100-400 bp was observed at 72 hours (green line) and larger fragments decreased (red circle). At 7 days, ucfDNA apparently degraded, but in group B, there was still a peak (red arrow).
| Profiles of ucfDNA fragment changes
However, in group C and group D, there were no significant changes of ucfDNA fragments distribution features from the preserved urine samples.
The electropherograms of the No. 9 urine sample are shown in Figure 4 . Compared with the fragments distribution at 2 hours, there was also no significant change at 24 hours in groups A and B, but an obvious decline in the peak at 150-400 bp was observed at 72 hours (green line) and larger fragments obviously decreased (red circle) in group A. At 7 days, ucfDNA degraded to nearly undetectable levels (red arrow). However, in group B, there was a reduction in relatively unusually large fragments (red arrow) and a relatively stable peak at approximately 200 bp. However, there were no obvious changes of ucfDNA fragments distribution features from the preserved urine samples.
| Slight changes of ucfDNA under experimental shipping conditions
To explore ucfDNA stabilization by using UCTs under experimental shipping conditions, 9 urine samples were collected to observe the 
| Small changes in allele fraction of preserved urine
To further investigate the original proportion and integrity of ucfDNA from the UCTs, the AF was detected using next-generation sequencing (NGS).We used a panel that contained genes associated with diseases of the urinary system, which can reflect changes of ucfDNA associated with the specific disease. As shown in Figure 6 , the Δ% of AF was used to measure the change of allele frequency variation in the ucfDNA. The average Δ% of AF of 7 days for groups B and D were 0.477% and 0.129%, respectively. The average Δ% of AF of group D was lower than group B by 3.7-fold, which suggested that the original proportion and integrity of ucfDNA from UCTs can be preserved well. If the original proportion and integrity of ucfDNA would have had a large change, the allele fraction would also be obviously changed, increasing, or decreasing.
| D ISCUSS I ON
Nuclease activity in urine is much higher than in blood, 9 so inhibiting nuclease activity is necessary during urine collection and storage.
F I G U R E 3 Electropherograms of ucfDNA samples No. 7. Groups A and B were, respectively, expressed samples without urinary cells and with urinary cells by using normal tubes, and groups C and D were, respectively, expressed samples without urinary cells and with urinary cells by using UCTs. The x-axis represents the different sizes of the marker; the valid region was between the lower and upper sizes. The y-axis represents the normalized sample intensity; the regions with high intensity demonstrate a high concentration
While there have been few reports about urine collection, only sterile containers have previously been required, even in remote areas. 33 An important factor limiting the effective use of urine collection is serious ucfDNA degradation; the half-life of ucfDNA is generally very short. In fact, compared with serum and saliva, urine contents have a much stronger effect on DNA degradation. 34 Previous studies demonstrated that in renal stone patients, ucfDNA in both the renal pelvis and voided urine was degraded under first-order kinetics with a half-life of 2.6-5.1 hours. 24 The rapid process of ucfDNA degradation may result in flawed accuracy and precision in the initial fragments profile and concentration. Urine contents can be correlated with urological tumors, stones, infections, or other physiological changes. The contents of urine from patients tend to be much more complex than urine from healthy individuals. EDTA is a chemical commonly used to protect DNA from degradation because it can inhibit nuclease activity. In some studies, EDTA was used to preserve ucfDNA at 4°C, quickly centrifuged to remove urinary sediment and stored at −80°C or −20°C or immediately extracted after sampling; F I G U R E 4 Electropherograms of ucfDNA samples No. 9. Groups A and B were, respectively, expressed samples without urinary cells and with urinary cells by using normal tubes, and groups C and D were, respectively, expressed samples without urinary cells and with urinary cells by using UCTs. The x-axis represents the different sizes of the marker; the valid region was between the lower and upper sizes. The y-axis represents the normalized sample intensity; the regions with high intensity demonstrate a high concentration F I G U R E 5 Preservative effect of ucfDNA by using UCTs under experimental shipping conditions. Urine samples were collected from 9 patients and placed on a vertical mixer at ambient temperature. Groups E and F were, respectively, expressed samples without urinary cells and with urinary cells by using normal tubes, and groups G and H were, respectively, expressed samples without urinary cells and with urinary cells by using UCTs. In each box plot, the line inside of the box indicates the median value; the limits of the box indicate the 75th and 25th percentiles. The upper and lower error bars, respectively, represent the 5th and 95th percentiles. The uppermost and lowermost plots represent the maximum and minimum values. Over time, statistically significant ucfDNA changes were not observed in groups G and H. Statistically significant ucfDNA time-dependent degradation was observed in groups E and F (*P < 0.05, **P < 0.01, ***P ≤ 0.001 by paired Student's t test) F I G U R E 6 Changes in allele fraction. NGS data were analyzed from five samples (No. 2, 5, 6, 7, 9) . Samples of groups B and D were, respectively, collected by normal tubes and UCTs with urinary cells and with urinary cells. The analysis results of 2 h for group B were the control of 7 days for group B, and the analysis results of 2 h for group D were the control of 7 days for group D. X-axis represents the Δ% of AF however, this procedure is difficult for widespread usage to maximally protect ucfDNA. 3, 11, 24, 25, 31, 35, 36 For potential biomarker use, the original proportion and integrity of ucfDNA is a very important factor in liquid biopsy. When the original proportion and integrity of ucfDNA is damaged, the target sequence may fail to amplify by PCR. Because the detection of most low-frequency mutations in liquid biopsies depends on DNA amplification, the original proportion and integrity of ucfDNA must be maintained. Another key factor affecting low-frequency mutation detection is background interference because of the degradation of longer ucfDNA and the release of cellular DNA originating from broken urinary cells can affect the proportion of the target ucfDNA.
Therefore, the allele frequency of the target ucfDNA may be influenced, especially for low-frequency alleles. The original proportion and integrity of ucfDNA can be protected by UCTs up to 7 days at ambient temperature.
The sample collection process is also an important preanalytical factor that can affect ucfDNA detection. Currently, the majority of ucfDNA studies have been performed at the same location where the urine was collected or close to urine collection site, and the urine sample must be placed at 4°C or a lower temperature and centrifuged immediately to minimize the ucfDNA degradation and release of cellular DNA. Thus, it is difficult to transport to another site. The new method that we had developed can be used to solve these preanalytical issues. We showed that UCTs can protect ucfDNA from degradation and can stabilize the urinary cells, thus ensuring that the original proportion and integrity of ucfDNA was maintained for up to 7 days at room temperature. This method provides an easier and more convenient way for collection, handling, shipment, and storage of urine.
| CON CLUS IONS
We found that ucfDNA was severely degraded in urine and that broken-down fragments of urinary cellular DNA were presumably released into the urine, which resulted in an increase of ucfDNA concentration without any protection for the original ucfDNA.
Using UCTs to preserve urine, the original proportion and integrity of ucfDNA can be maintained and the urinary cells can be stabilized to minimize the release of cellular DNA and degradation for up to 7 days. Even under simulated long-term shipping conditions, the ucfDNA stability was very high. The limitation of our study was the lack of a direct experimental comparison between UCTs and EDTA tubes to evaluate the preserving effect, which deserved further detailed investigation.
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